Dashboard
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 12.99%
- Healthy long term growth as Net Sales has grown by an annual rate of 8.92%
- Company has very low debt and has enough cash to service the debt requirements
The company has declared Negative results for the last 4 consecutive quarters
With ROE of 12.06%, it has a expensive valuation with a 2.83 Price to Book Value
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
COSMOS Pharmaceutical Corp. for the last several years.
Risk Adjusted Returns v/s 
News

COSMOS Pharmaceutical Corp. Hits Day Low at JPY 7,291 Amid Price Pressure
COSMOS Pharmaceutical Corp. faced notable stock volatility on October 15, 2025, with a significant decline amid broader market trends. While the company has shown resilience over the past year, its long-term performance raises concerns, particularly with consecutive quarterly losses despite solid financial metrics indicating fundamental strength.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Aug 2024
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 1 Foreign Institutions (0.02%)
Quarterly Results Snapshot (Consolidated) - Feb'25 - QoQ
QoQ Growth in quarter ended Feb 2025 is 0.92% vs -6.78% in Nov 2024
QoQ Growth in quarter ended Feb 2025 is 25.93% vs -22.82% in Nov 2024
Annual Results Snapshot (Consolidated) - May'24
YoY Growth in year ended May 2024 is 16.59% vs 9.57% in May 2023
YoY Growth in year ended May 2024 is 2.76% vs 2.77% in May 2023






